Prevention of Venous Thromboembolism in 2020 and Beyond
Open accessThe DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Abstract
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830 · cited 1×
“One important exception to this recommendation is the case of low-risk isolated subsegmental PE with normal ultrasonography of the legs, which should be managed with clinical surveillance over anticoagulation [36].”
BackgroundCRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., Merdji, H., Clere-Jehl, R., Schenck, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06062-x · Cited by 2,792 · cited 1×
“In a study of two French intensive care units that utilized systematic screening with compression ultrasound 1–3 days after admission, the proportion of patients with VTE was 69%, with 23% of patients diagnosed with pulmonary embolism despite prophylaxis, and in some cases despite therapeutic anticoagulation [149,150].”
BackgroundSilverstein, M. D., Heit, J. A., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.585 · Cited by 2,660 · cited 2×
“During childbearing years, the incidence of VTE increases in women, and in the third decade of life, the risk of first VTE events in women exceeds that in men [15,42].”
BackgroundCOVID-19 and its implications for thrombosis and anticoagulation
Connors, J. M., & Levy, J. H. (2020) · Blood · doi:10.1182/blood.2020006000 · Cited by 2,369 · cited 2×
“of evidence suggests that immunothrombosis contributes to in situ development of pulmonary artery thrombi [138,142,143].”
BackgroundDevelopment and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,171
Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., Kucher, N., Studt, J.-D., Sacco, C., Bertuzzi, A., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.024 · Cited by 2,054 · cited 1×
“5%, and a rate of positive imaging tests of 46%, potentially indicating underdiagnosis in this population [144].”
BackgroundIncidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
Pengo, V., Lensing, A. W. A., Prins, M. H., Marchiori, A., Davidson, B. L., Tiozzo, F., Albanese, P., Biasiolo, A., Pegoraro, C., Iliceto, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032274 · Cited by 1,828 · cited 1×
“The prevalence of CTEPH after VTE varies significantly in the literature and is estimated at 3–4% [46,47].”
BackgroundPrevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
Cui, S., Chen, S., Li, X., Liu, S., & Wang, F. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14830 · Cited by 1,806 · cited 2×
“The development of VTE in COVID-19 patients appears to correlate with more severe disease course, higher D-dimer, higher CRP, and mortality [142,146,151].”
BackgroundMethod
Cited by
O’Sullivan, J. W., Raghavan, S., Marquez-Luna, C., Luzum, J. A., Damrauer, S. M., Ashley, E. A., O’Donnell, C. J., Willer, C. J., Natarajan, P., & on behalf of the American Heart Association Council on Genomic and Precision Medicine; Council on Clinical Cardiology; Council on Arteriosclerosis, T. A. V. B. C. O. C. R. A. I. C. O. L. A. C. H. A. C. O. P. V. D. (2022) · Circulation · doi:10.1161/cir.0000000000001077 · Cited by 412
Metadata
- Authors
- Nicholson, M., Chan, N., Bhagirath, V., & Ginsberg, J.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 2467
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3046665734
- Cited by
- 224
- References
- 170
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.